GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Cyclically Adjusted PS Ratio

Novartis AG (MEX:NVS N) Cyclically Adjusted PS Ratio : 4.81 (As of Jun. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted PS Ratio?

As of today (2024-06-25), Novartis AG's current share price is MXN1851.08. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was MXN384.91. Novartis AG's Cyclically Adjusted PS Ratio for today is 4.81.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:NVS N' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.83   Med: 3.71   Max: 4.59
Current: 4.58

During the past years, Novartis AG's highest Cyclically Adjusted PS Ratio was 4.59. The lowest was 2.83. And the median was 3.71.

MEX:NVS N's Cyclically Adjusted PS Ratio is ranked worse than
79.3% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.055 vs MEX:NVS N: 4.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's adjusted revenue per share data for the three months ended in Mar. 2024 was MXN97.834. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN384.91 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 3.98 3.84 3.88 4.09

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 4.11 4.28 4.09 4.17

Competitive Comparison of Novartis AG's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.



Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1851.08/384.91
=4.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=97.834/107.3549*107.3549
=97.834

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 73.214 101.517 77.425
201409 72.593 101.247 76.972
201412 80.135 100.704 85.428
201503 76.050 100.339 81.368
201506 82.554 100.464 88.217
201509 86.535 99.785 93.100
201512 90.977 99.386 98.271
201603 84.778 99.475 91.494
201606 97.659 100.088 104.750
201609 99.383 99.604 107.117
201612 108.562 99.380 117.274
201703 92.884 100.040 99.676
201706 95.171 100.285 101.880
201709 97.641 100.254 104.557
201712 53.557 100.213 57.374
201803 86.410 100.836 91.997
201806 97.603 101.435 103.299
201809 91.093 101.246 96.590
201812 99.785 100.906 106.162
201903 95.000 101.571 100.410
201906 99.000 102.044 104.153
201909 107.279 101.396 113.584
201912 103.955 101.063 110.427
202003 130.007 101.048 138.122
202006 116.432 100.743 124.073
202009 120.320 100.585 128.419
202012 113.482 100.241 121.536
202103 114.560 100.800 122.010
202106 117.197 101.352 124.138
202109 121.940 101.533 128.933
202112 41.982 101.776 44.283
202203 114.054 103.205 118.640
202206 119.061 104.783 121.984
202209 99.495 104.835 101.887
202212 99.070 104.666 101.615
202303 93.926 106.245 94.907
202306 114.042 106.576 114.876
202309 101.508 106.570 102.256
202312 96.378 106.461 97.187
202403 97.834 107.355 97.834

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (MEX:NVS N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (MEX:NVS N) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (MEX:NVS N) Headlines

No Headlines